29 Emmons Drive
285 articles with Soligenix
Soligenix Receives Orphan Drug Designation from the European Commission for RiVax® for Prevention of Ricin Poisoning
The European Commission, acting on the positive recommendation from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products, has granted orphan drug designation to the Company's recombinant modified ricin toxin A-chain subunit (the active pharmaceutical ingredient in RiVax®) for the prevention of ricin poisoning.
Announced today its recent accomplishments and financial results for the year ended December 31, 2017.
Soligenix, Inc. announced that its Chief Financial Officer, Karen Krumeich, will deliver a corporate presentation at the 12th Annual International Partnering Conference Bio-Europe Spring in Amsterdam, Wednesday, March 14 at 10:00 AM GMT.
Soligenix today issued an update letter from its President and CEO, Dr. Christopher J. Schaber.
Soligenix announced today that the U.S. Patent Office has granted the patent entitled "Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis."
Soligenix announced today that biomarkers for ricin toxin vaccine testing have been successfully identified, facilitating potential approval under the FDA "Animal Rule".
Soligenix to Receive $417,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
Soligenix announced today that it has received preliminary approval for a tax credit from the NJEDA's New Jersey Technology Business Tax Certificate Transfer program.
Soligenix announced today its recent accomplishments and financial results for the third quarter ended September 30, 2017.
Soligenix Announces Closing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above Market
Lead investors in the financing included Knoll Capital Management, LP and ACT Capital Management, LLLP.
Soligenix Announces Pricing of $5,115,000 Concurrent Registered Direct Offering and Private Placement of Common Stock Priced Above Market
Soligenix announced that it has entered into definitive agreements with investors for the purchase and sale of 1,575,500 shares of common stock at a price of $2.00 per share in a registered direct offering and 982,000 shares of common stock at a purchase price of $2.00 per share in a concurrent private placement.
Soligenix Announces $700,000 Subaward Supporting Development Collaboration On Thermostabilization Of An Ebola Vaccine Candidate
Soligenix Announces $1.5 Million NIDCR SBIR Grant Award Supporting The Pivotal Phase III Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer
Soligenix Announces $1.5 Million NCI SBIR Grant Award Supporting The Pivotal Phase III Clinical Trial Of SGX301 For The Treatment Of Cutaneous T-Cell Lymphoma
Soligenix Receives $2.5M In Additional NIAID Funding To Advance Development Of Heat Stable Ricin Vaccine
Soligenix Initiates Pivotal Phase III Clinical Trial Of SGX942 (Dusquetide) For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients
Soligenix Release: Dusquetide Technology Platform To Be Presented At The 2017 Drug Discovery And Therapy World Congress
Soligenix Release: Complete Efficacy And Long-Term Follow-Up Safety Results From SGX942 Phase II Oral Mucositis Clinical Trial To Be Presented At The 2017 Multinational Association For Supportive Care In Cancer Conference
Soligenix Announces Publication Of Its Phase II Long-term Follow-up Results Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients